Why the study?
Does the Asn291Ser variant of the LPL gene interact with insulin resistance to worsen dyslipidaemia in individuals at high risk for Type 2 diabetes?
Does the Asn291Ser variant of the LPL gene interact with insulin resistance to worsen dyslipidaemia in individuals at high risk for Type 2 diabetes?
The Asn291Ser variant of the LPL gene exacerbates dyslipidaemia in normoglycaemic individuals, particularly those with insulin resistance, highlighting a genetic-metabolic interaction in cardiovascular risk.
No takes yet. Share an insight, caveat, or question.
Does not support clinical genotyping yet; leaves open whether the interaction predicts incident cardiovascular events in prospective cohorts.
Klannemark et al. (2000) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: